French Firm Explores U.S. Regulatory Strategy For Blood-based Alzheimer’s Test
This article was originally published in The Gray Sheet
Executive Summary
With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.